Clinical trial · Interventional
RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients
Prospective Controlled Randomized Comparative Study About Quality of Life (QoL), Immunomodulation and Safety of Adjuvant Mistletoe Treatment in Patients With Gastric Carcinoma Receiving Chemotherapy After Operation
NCT01401075CI-TRIAL-00008434completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation of safety and efficacy of a standardized mistletoe extract (abnobaVISCUM® Quercus, aVQ) in patients with gastric cancer receiving oral chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| doxifluridine | Drug | — | UNRESOLVED |
| mistletoe extract | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- doxifluridine
- description
- oral chemotherapy with the 5-FU prodrug doxifluridine
- interventionNames
- Drug: doxifluridine
- type
- EXPERIMENTAL
- label
- doxifluridine + mistletoe extract
- description
- oral chemotherapy with the 5-FU prodrug doxifluridine + mistletoe extract as subcutaneous injection
- interventionNames
- Drug: mistletoe extract
- Drug: doxifluridine
Primary outcomes (1)
- measure
- Quality of Life
- timeFrame
- 24 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * postoperative UICC stage Ib/II gastric carcinoma * indication for oral chemotherapy with doxifluridine * ECOG performance status 0 or 1 * normal liver and kidney function Exclusion Criteria: * inability to answer the QoL scales * concomitant therapy with steroids or biological response modifiers * individual hypersensitivity to mistletoe preparations * pregnancy or lactating * participation in another clinical trial
References
Publications (1)
- RESULTKim KC, Yook JH, Eisenbraun J, Kim BS, Huber R. Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study. BMC Complement Altern Med. 2012 Oct 3;12:172. doi: 10.1186/1472-6882-12-172. PMID 23033982